Pages that link to "Q34167899"
Jump to navigation
Jump to search
The following pages link to Adverse effects of long-term proton pump inhibitor therapy (Q34167899):
Displaying 50 items.
- The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis (Q21090577) (← links)
- Overutilization of proton-pump inhibitors: what the clinician needs to know (Q24634086) (← links)
- Biomarkers and Algorithms for the Diagnosis of Vitamin B12 Deficiency (Q26742072) (← links)
- Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice (Q28249795) (← links)
- Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis (Q30234653) (← links)
- A Comprehensive Look at Polypharmacy and Medication Screening Tools for the Older Cancer Patient (Q30276856) (← links)
- Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? (Q30620638) (← links)
- ATP4a is required for development and function of the Xenopus mucociliary epidermis - a potential model to study proton pump inhibitor-associated pneumonia. (Q30666695) (← links)
- Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis (Q33564258) (← links)
- A Retrospective Study to Assess the Effect of Proton Pump Inhibitors on Renal Profile in a South Indian Hospital (Q33741655) (← links)
- Antiplatelet drug interactions with proton pump inhibitors (Q33948811) (← links)
- Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications (Q33949498) (← links)
- Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. (Q34286825) (← links)
- Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility (Q34566765) (← links)
- The proton-pump inhibitor lansoprazole enhances amyloid beta production (Q34631939) (← links)
- Antiulcerogenic activity of chlorogenic acid in different models of gastric ulcer (Q34660906) (← links)
- Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model (Q34734891) (← links)
- The use of natural health products by paediatric patients in respite care (Q35099144) (← links)
- Are proton pump inhibitors a new antidiabetic drug? A cross sectional study (Q35615391) (← links)
- Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study (Q35899886) (← links)
- Mechanism(s) of action underlying the gastroprotective effect of ethyl acetate fraction obtained from the crude methanolic leaves extract of Muntingia calabura (Q35934917) (← links)
- An automated tool for detecting medication overuse based on the electronic health records (Q36592533) (← links)
- Tissue acquisition in gastric epithelial tumor prior to endoscopic resection. (Q37232789) (← links)
- The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. (Q37381765) (← links)
- The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. (Q37395858) (← links)
- Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection-a cross-sectional population-based study (Q37596015) (← links)
- Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem? (Q37704535) (← links)
- Proton pump inhibitors: impact on glucose metabolism (Q38034083) (← links)
- The role of the gastrointestinal tract in calcium homeostasis and bone remodeling (Q38093799) (← links)
- Indications and safety of proton pump inhibitor drug use in patients with cancer (Q38104388) (← links)
- Anti-ulcer activity of essential oil constituents. (Q38209865) (← links)
- Gastrogastric fistulae following gastric bypass surgery-clinical recognition and treatment (Q38238978) (← links)
- Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications (Q38317967) (← links)
- Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. (Q38547653) (← links)
- Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan (Q38645653) (← links)
- A Case of Severe Iron Deficiency Anemia Associated with Long-Term Proton Pump Inhibitor Use. (Q38650471) (← links)
- Potentially inappropriate prescribing in a population of frail elderly people (Q38784124) (← links)
- Acid-Suppressive Therapy and Risk of Infections: Pros and Cons (Q38865456) (← links)
- A Closer Look at the 2015 Beers Criteria (Q38947477) (← links)
- Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia: case review (Q39080559) (← links)
- Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype (Q39115196) (← links)
- Proton pump inhibitor failure in gastro-oesophageal reflux disease: a perspective aided by the Gartner hype cycle. (Q39157567) (← links)
- Inhibition of lysosomal enzyme activities by proton pump inhibitors (Q39182584) (← links)
- A Comparison of Alkaline Water and Mediterranean Diet vs Proton Pump Inhibition for Treatment of Laryngopharyngeal Reflux (Q40053716) (← links)
- Micromotor-enabled active drug delivery for in vivo treatment of stomach infection (Q40090937) (← links)
- New Approaches to Gastroesophageal Reflux Disease (Q40169026) (← links)
- Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence? (Q40852115) (← links)
- Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013. (Q41132376) (← links)
- Effect of proton pump inhibitors on glycemic control in patients with diabetes (Q42116846) (← links)
- Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression (Q42371575) (← links)